Infectious Diseases and Medical Intensive Care Unit, Pontchaillou University Hospital, 2, rue Henri Le Guilloux, 35033, Rennes Cedex 9, France.
Internal Medicine and Clinical Immunology, Pontchaillou University Hospital, Rennes, France.
Eur J Clin Microbiol Infect Dis. 2021 Nov;40(11):2437-2442. doi: 10.1007/s10096-021-04245-y. Epub 2021 Apr 28.
We conducted an observational retrospective study of all adults hospitalized for documented varicella-zoster virus (VZV) meningitis or encephalitis during years 2000-2015 in one referral centre. Thirty-six patients (21 males, 15 females) were included, with meningitis (n = 21), or meningoencephalitis (n = 15). Median age was 51 years [interquartile range, 35-76], and 6 patients (17%) were immunocompromised. Aciclovir was started in 32 patients (89%), with a median dose of 11 mg/kg/8 h [10-15]. No patient died, but 12 (33%) had neurological sequelae at discharge. Age was the only variable associated with adverse outcome (OR 1.98 [1.17-3.35] per 10-year increment, P = 0.011).
我们对 2000 年至 2015 年间在一家转诊中心住院的所有确诊水痘带状疱疹病毒（VZV）脑膜炎或脑炎的成年人进行了一项观察性回顾性研究。共纳入 36 例患者（21 例男性，15 例女性），包括脑膜炎（n=21）或脑膜脑炎（n=15）。中位年龄为 51 岁[四分位距，35-76]，6 例（17%）患者免疫功能低下。32 例（89%）患者开始使用阿昔洛韦，中位剂量为 11 mg/kg/8 h[10-15]。无患者死亡，但 12 例（33%）出院时存在神经后遗症。年龄是唯一与不良预后相关的变量（每增加 10 岁，OR 1.98[1.17-3.35]，P=0.011）。
